IMPROVING COVID-19 VACCINATION UPTAKE IN HIV POSITIVE PREGNANT WOMEN IN NIGERIA

提高尼日利亚 HIV 阳性孕妇的 COVID-19 疫苗接种率

• 批准号: 10619475
• 负责人: Alash'le G. Abimiku
• 金额: $ 14.22万
• 依托单位: INSTITUTE OF HUMAN VIROLOGY
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-09-01 至 2024-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10619475
• 关键词: 2019-nCoV; Address; Adult; Affect; Africa; African; Birth History; COVID-19; COVID-19 pandemic; COVID-19 vaccination; COVID-19 vaccine; Cohort Studies; Country; Data; Decision Making; Developing Countries; Education; Educational Materials; Focus Groups; Funding; Future; Grant; Guidelines; HIV; HIV Infections; HIV Seropositivity; HIV-1; Healthcare Systems; Hospitals; Immune response; Improve Access; Infant; Infection; Infrastructure; Interviewer; Literature; Mothers; Natural History; Nigeria; Nigerian; Normalcy; Passive Transfer of Immunity; Persons; Policies; Policy Maker; Population; Pregnant Women; Preparation; Prevalence; Prevention; Public Health; Questionnaires; Research; Resources; SARS-CoV-2 antibody; Shapes; Soldier; Structure; Testing; Time; Travel; United States National Institutes of Health; Vaccinated; Vaccination; Vaccines; Vulnerable Populations; Woman; base; design; experience; fighting; improved; insight; pandemic disease; population based; pregnant; prospective; response; social; social culture; success; unvaccinated; vaccine acceptance; vaccine access; vaccine hesitancy

A. Project Summary/Abstract With the current global devastation and loss of lives, livelihood, and share suffering as a result of the COVID-19 pandemic, especially with the weak health care systems and limited resources in Africa, there is need to conduct research that will provide valuable information on treatment and prevention options and to understand the peculiarities of different populations as they respond. The effective COVID-19 vaccines have been largely instrumental to success in fighting the pandemic in the last 18 months. While most countries in the developed world have vaccinated over 70% of their population, only 21 African countries have fully vaccinated between 10% and 19% of their populations. Nigeria has only vaccinated 7.2% of its adult population and boosted only 0.4% and there is currently no data of vaccination in pregnant women or HIV infected persons. Even with the improved access of vaccines to Africa, vaccine hesitancy continues to limit the ability to improve vaccine coverage in these countries. Our ongoing NIH funded BEAMING grant (5U01HD094658) situated at a tertiary hospital where we have conducted research for over 20 years and including two prospective natural history birth cohort studies in HIV is uniquely placed to rapidly provide information for the first time from this part of the world that is this vulnerable population. This supplemental submission builds on the BEAMING experience and infrastructure to address research questions of great public health importance on social and culture norms that could explain vaccine hesitancy in this vulnerable population. We plan to use the information to develop culturally and socially acceptable educational materials and sessions that target drivers of vaccine hesitancy in HIV pregnant women and their matched uninfected pregnant controls in Nigeria, with the objective of re-shaping policies and strategies towards improved COVID-19 vaccines uptake in preparation for other waves of SARS COV-2 or future pandemics through three specific aims. Aim 1 will document social and cultural reasons for COVID-19 vaccine hesitancy among pregnant women in Nigeria and whether HIV infection creates an additional layer of burden. Aim 2 will develop strategies and educational materials to improve COVID-19 vaccine hesitancy and coverage in this population based on responses obtained from Aim 1. Aim 3 will document for the presence of anti- SARS-CoV-2 antibodies in infected pregnant women with or without HIV-1 infection; and if possible, the presence of anti- SARS-CoV-2 passively transferred antibodies in their infants.

A.项目摘要/摘要 在当前的全球破坏和生命、生计和分担痛苦的情况下， 新冠肺炎大流行，特别是在卫生保健系统薄弱和资源有限的情况下 在非洲，需要进行研究，提供关于治疗和治疗的有价值的信息 预防方案，并在应对时了解不同人群的特点。 有效的新冠肺炎疫苗在很大程度上有助于成功抗击 在过去的18个月里发生了大流行。虽然发达国家的大多数国家都接种了疫苗 超过70%的人口，只有21个非洲国家完全接种了10%到10%的疫苗 占其人口的19%。尼日利亚只为7.2%的成年人口接种了疫苗，并提高了 只有0.4%，目前没有孕妇或感染艾滋病毒的妇女接种疫苗的数据 人。即使疫苗进入非洲的机会有所改善，疫苗的犹豫不决仍然是有限的 提高这些国家疫苗覆盖率的能力。我们正在进行的由美国国立卫生研究院资助的 Grant(5U01HD094658)位于我们进行研究的一家三级医院 20多年来，包括两项关于艾滋病毒的前瞻性自然史出生队列研究 独一无二的位置，第一次快速提供来自世界这一地区的信息 这就是这些脆弱的人群。这份补充提交的材料建立在 解决具有重大公共卫生重要性的研究问题的经验和基础设施 关于社会和文化规范，这可以解释疫苗在这一脆弱人群中的犹豫不决。 我们计划利用这些信息来发展文化和社会可接受的教育 针对HIV孕妇和他们的疫苗迟疑的驱动因素的材料和课程 在尼日利亚匹配未感染的孕妇对照，目标是重新制定政策和 为应对其他SARS浪潮而提高新冠肺炎疫苗接种率的策略 CoV-2或未来的大流行通过三个具体目标。目标1将记录社会和文化 尼日利亚孕妇对新冠肺炎疫苗犹豫不决的原因以及艾滋病毒 感染造成了额外的负担。目标2将制定战略和教育 改善新冠肺炎疫苗在这一人群中的迟疑性和覆盖率的材料 从AIM 1获得的答复。AIM 3将记录抗SARS-CoV-2的存在 感染HIV-1或不感染HIV-1的孕妇的抗体；如有可能， 婴儿中存在抗SARS-CoV-2被动转移抗体。